{"id":52652,"date":"2023-01-06T20:02:23","date_gmt":"2023-01-06T19:02:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/"},"modified":"2023-01-06T20:02:23","modified_gmt":"2023-01-06T19:02:23","slug":"hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/","title":{"rendered":"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603"},"content":{"rendered":"
\n

\nHFB200603 is a novel anti-BTLA Antibody for the treatment of DIS\u2122 Defined Solid Tumors<\/i>\n<\/p>\n

<\/a><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DIS<\/a>–HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company\u2019s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel monoclonal antibody against the immune checkpoint BTLA that blocks the interaction with its ligand, HVEM. HFB200603 is designed to reverse HVEM-mediated immune suppressive effects and induce the production of inflammatory cytokines in various solid tumors selected by HiFiBiO\u2019s proprietary Drug Intelligence Science (DIS\u2122) platform.\n<\/p>\n

\n\u201cThe FDA\u2019s clearance of our IND for HFB200603 marks our third consecutive successful IND for a therapeutic antibody targeting DIS\u2122 defined solid tumors\u201d, said co-founder and CEO of HiFiBiO Therapeutics, Liang Schweizer, Ph.D. \u201cThis is continuing validation of the strength of our single cell-powered DIS\u2122 platform to identify and develop novel drugs.\u201d\n<\/p>\n

\n\u201cWe are excited to bring our BTLA clinical candidate HFB200603 to patients and translate the promising preclinical data obtained in our labs into meaningful clinical benefit\u201d shared Francisco Adri\u00e1n, Ph.D., CSO of HiFiBiO Therapeutics. \u201cHFB200603 has demonstrated its ability to stimulate tumor infiltrating lymphocytes and to potentiate the immunomodulatory effects of PD-1 blockade in human tumor cultures from different cancer types.\u201d\n<\/p>\n

\nThe planned Phase 1 clinical study will consist of an initial dose escalation followed by expansion cohorts, including combination treatment with Novartis\u2019 Tislelizumab, in selected solid tumors identified through HiFiBiO DIS\u2122 platform.\n<\/p>\n

\nHFB200603
\n
<\/b>HFB200603 was identified using HiFiBiO single cell platform as a single-digit nanomolar binder to human and cynomolgus BTLA, capable of blocking BTLA interaction with its ligand HVEM, reversing HVEM-mediated immune suppressive effects, and inducing the production of inflammatory cytokines in the tumor microenvironment of different human tumor types. HFB200603 synergizes with anti-PD-1 and demonstrates favorable developability, pharmacokinetic and safety profiles.\n<\/p>\n

\nAbout HiFiBiO Therapeutics
\n
<\/b>HiFiBiO Therapeutics is a clinical stage biotech company advancing a robust pipeline targeting both the innate and adaptive immunity to treat cancer and autoimmune diseases. Its proprietary and versatile DIS\u2122 single-cell platform enables the rapid discovery of novel antibody therapeutics with predictive biomarkers through our internal development programs and strategic collaborations. Our passionate team across three continents embraces a fast-paced and engaging work environment to bring transformative medicines to patients. www.hifibio.com<\/a>\n<\/p>\n

\nHiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS are trademarks of HiFiBiO and its affiliates.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Vincent Tse
\n
media@hifibio.com<\/a>
(617) 395-1212\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HFB200603 is a novel anti-BTLA Antibody for the treatment of DIS\u2122 Defined Solid Tumors CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DIS–HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company\u2019s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel monoclonal antibody against the immune checkpoint BTLA that … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52652","6":"format-standard","7":"category-industry"},"yoast_head":"\nHiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HFB200603 is a novel anti-BTLA Antibody for the treatment of DIS\u2122 Defined Solid Tumors CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DIS–HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company\u2019s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel monoclonal antibody against the immune checkpoint BTLA that ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-06T19:02:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230106005407\/en\/815913\/21\/Logo-RGB-300.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603\",\"datePublished\":\"2023-01-06T19:02:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/\"},\"wordCount\":415,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005407\\\/en\\\/815913\\\/21\\\/Logo-RGB-300.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/\",\"name\":\"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005407\\\/en\\\/815913\\\/21\\\/Logo-RGB-300.jpg\",\"datePublished\":\"2023-01-06T19:02:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005407\\\/en\\\/815913\\\/21\\\/Logo-RGB-300.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005407\\\/en\\\/815913\\\/21\\\/Logo-RGB-300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/","og_locale":"en_US","og_type":"article","og_title":"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 - Pharma Trend","og_description":"HFB200603 is a novel anti-BTLA Antibody for the treatment of DIS\u2122 Defined Solid Tumors CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DIS–HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company\u2019s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel monoclonal antibody against the immune checkpoint BTLA that ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-06T19:02:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230106005407\/en\/815913\/21\/Logo-RGB-300.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603","datePublished":"2023-01-06T19:02:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/"},"wordCount":415,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230106005407\/en\/815913\/21\/Logo-RGB-300.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/","url":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/","name":"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230106005407\/en\/815913\/21\/Logo-RGB-300.jpg","datePublished":"2023-01-06T19:02:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230106005407\/en\/815913\/21\/Logo-RGB-300.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230106005407\/en\/815913\/21\/Logo-RGB-300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52652"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52652\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}